Australia's Vaxine eyes coronavirus vaccine trial in Philippines â DOST
In this file photo capped vials are being pictured during filling and packaging tests for the large-scale production and supply of the University of Oxford’s Covid-19 vaccine candidate, AZD1222, on a high-performance aseptic vial filling line on September 11, 2020 at the Italian biologics’ manufacturing facility of multinational corporation Catalent in Anagni, southeast of Rome, during the COVID-19 infection, caused by the novel coronavirus.
AFP/Vincenzo Pinto
Australia's Vaxine eyes coronavirus vaccine trial in Philippines — DOST
Gaea Katreena Cabico (Philstar.com) - October 26, 2020 - 5:56pm

MANILA, Philippines — Australian company Vaxine Pty Ltd has expressed interest in conducting a clinical trial of its coronavirus vaccine candidate in the country, the Department of Science and Technology said Monday.

DOST Secretary Fortunato de la Peña said the biotechnology firm based in Australia has informed the department that it is willing to conduct clinical trial and manufacturing of its potential vaccines against COVID-19 in the Philippines.

“It is quite recent in terms of expressing interest,” de la Peña said in a forum organized by the Foreign Correspondents Association of the Philippines. He did not provide other details.

According to the coronavirus vaccine tracker of the New York Times, Vaxine’s candidate vaccine combines “viral proteins with an adjuvant that stimulates the immune system.”

The Phase 2 trial for the candidate vaccine is expected to begin by the end of the year. Phase 2 studies involve up to several hundred individuals and aim to define the optimal dose and safety profile of vaccine candidates.

Earlier, the vaccine candidate of Chinese drug maker Sinovac Biotech hurdled the initial stage of screening for clinical trials in the country after passing the review of the vaccine experts panel chaired by the DOST. It is still undergoing the evaluation of the Single Joint Ethics Research Board.

The World Health Organization-led solidarity trial for COVID-19 vaccines will start in September in the Philippines. It was initially scheduled to begin by end-October.

The country is in talks with 17 companies as it seeks to source a vaccine that will help end one of the worst outbreaks in Southeast Asia.

The Philippines' COVID-19 caseload reached 371,630 Monday, with 7,039 deaths. 

COVID-19 VACCINES NOVEL CORONAVIRUS
As It Happens
LATEST UPDATE: November 23, 2020 - 5:20pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

November 23, 2020 - 5:20pm

European stock markets opened firmer Monday, buoyed as positive news on another coronavirus vaccine trial helped offset concerns over soaring case numbers, dealers said.

In London, the FTSE 100 index of leading shares was up 0.5 percent at 6,382.36 points.

In the Eurozone, the Paris CAC 40 gained nearly one percent to 5,543.83 points and the Frankfurt DAX put on 0.6 percent to 13,219.25 points.

Shortly before the markets opened, British drugs group AstraZeneca and the University of Oxford said their jointly-developed vaccine against COVID-19 has shown "an average efficacy of 70 percent" in trials, and up to 90 percent in one dosage combination. — AFP

November 23, 2020 - 10:34am

The United States hopes to begin coronavirus vaccinations in early December, a top government health official said Sunday, the latest positive news to emerge even as cases surge across the worst-hit nation and elsewhere around the globe.

The beginning of vaccinations could be a crucial shift in the battle against a virus that has claimed more than 1.4 million lives worldwide, including 255,000 just in the US, since emerging from China late last year.

Encouraging results from vaccine trials have bolstered hopes for an end to the pandemic, as nations reimpose restrictions and lockdowns that slowed the spread earlier this year but turned lives and economies upside down across the globe. — AFP

November 19, 2020 - 8:31pm

A leading COVID-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said Thursday as it released its phase 2 trial results.

The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side effects in people aged 56 and over than in younger people — a significant finding given that COVID-19 disproportionately causes severe illness among seniors. 

The manufacturers said the vaccine was undergoing larger, more comprehensive phase 3 trials to confirm the results. — AFP

November 18, 2020 - 8:34pm

The biotech company Pfizer says Wednesday that a completed study of its experimental COVID-19 vaccine showed it is 95% effective.

Pfizer says the vaccine had no serious side effects and that the company will apply for emergency use authorization from US regulators within a matter of days.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," says Pfizer CEO Albert Bourla. — AFP

November 18, 2020 - 9:34am

Pfizer is "very close" to applying for an emergency use approval for its COVID-19 vaccine after collecting safety data to submit to US regulators, the company's CEO said Tuesday, according to a report. 

The pharmaceutical giant announced last week preliminary results from a late-stage clinical trial showing the injections it had co-developed with Germany's BioNTech was more than 90 percent effective after the second dose.

"We are very close to submitting for an emergency use authorization," Albert Bourla says. "We will announce it as soon as we are doing it." 

— AFP

Philstar
  • Latest
  • Trending
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with